First Report for the Electrochemical Determination and Proposed Mechanism of Poly(Adp Ribose) Polymerase Inhibitor and New Smart Anticancer Drug Olaparib

Abstract

A sensitive, rapid, and inexpensive electrochemical method with an unmodified carbon paste electrode (CPE) was developed for the first time for voltammetric determination of poly(ADP-Ribose) polymerase (PARP) inhibitor olaparib (OLA) used in the treatment of advanced ovarian cancer, metastatic breast, and prostate cancer. OLA showed an irreversible oxidation peak at physiological pH (pH 7.4) at approximately + 1.31 V by the cyclic voltammetry technique. Using the suitable values of square-wave voltammetric parameters, the CPE showed good linearity in the concentration ranges of 5.8 x 10(-7)-4.6 x 10(-5) mol dm(-3) for OLA. The limit of detection and limit of quantification were determined to be 2.9 x 10(-8) and 9.7 x 10(-8) mol dm(-3) for OLA, respectively. Besides its high stability and reproducibility, the response of OLA at CPE was not affected in the presence of dopamine, uric acid, and ascorbic acid. The developed electrochemical method has been successfully applied for the detection of OLA in the spiked human urine sample.{GRAPHICAL ABSTRACT}